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Abstract
VTI1A-TCF7L2 was reported as a recurrent fusion gene in colorectal cancer (CRC), found to be expressed in three out of 97
primary cancers, and one cell line, NCI-H508, where a genomic deletion joins the two genes [1]. To investigate this fusion
further, we analyzed high-throughput DNA and RNA sequencing data from seven CRC cell lines, and identified the gene
RP11-57H14.3 (ENSG00000225292) as a novel fusion partner for TCF7L2. The fusion was discovered from both genome and
transcriptome data in the HCT116 cell line. By triplicate nested RT-PCR, we tested both the novel fusion transcript and VTI1A-
TCF7L2 for expression in a series of 106 CRC tissues, 21 CRC cell lines, 14 normal colonic mucosa, and 20 normal tissues from
miscellaneous anatomical sites. Altogether, 42% and 45% of the CRC samples expressed VTI1A-TCF7L2 and TCF7L2-RP11-
57H14.3 fusion transcripts, respectively. The fusion transcripts were both seen in 29% of the normal colonic mucosa samples,
and in 25% and 75% of the tested normal tissues from other organs, revealing that the TCF7L2 fusion transcripts are neither
specific to cancer nor to the colon and rectum. Seven different splice variants were detected for the VTI1A-TCF7L2 fusion, of
which three are novel. Four different splice variants were detected for the TCF7L2-RP11-57H14.3 fusion. In conclusion, we
have identified novel variants of VTI1A-TCF7L2 fusion transcripts, including a novel fusion partner gene, RP11-57H14.3, and
demonstrated detectable levels in a large fraction of CRC samples, as well as in normal colonic mucosa and other tissue
types. We suggest that the fusion transcripts observed in a high frequency of samples are transcription induced chimeras
that are expressed at low levels in most samples. The similar fusion transcripts induced by genomic rearrangements
observed in individual cancer cell lines may yet have oncogenic potential as suggested in the original study by Bass et al.
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Introduction
Colorectal cancer (CRC) is the second most common and
deadly cancer disease world-wide [2], and there is high demand of
good biomarkers for both early detection and to stratify patients
according to prognosis and predicted treatment responses.
However, CRC is a heterogeneous disease, and few biomarkers
have yet made it to routine clinical use.
Fusion genes represent one class of cancer genes with promising
biomarker potential, and when caused by chromosomal rear-
rangements such as translocations, deletions or duplications, they
are commonly highly cancer specific. So far, few highly recurrent
fusion genes have been identified in CRC. Examples from other
cancer types includes the well-known BCR-ABL1 fusion (Philadel-
phia chromosome), present in 95% of chronic myelogenous
leukemias [3], and TMPRSS2-ERG which is present in around
50% of prostate cancers [4]. In some cases, the fusion gene can be
a therapeutic target, demonstrated by Imatinib binding to and
blocking the kinase domain of the BCR-ABL1 fusion protein.
The first fusion gene reported to be recurrent in CRC, fusing
sequences of VTI1A and TCF7L2, was reported in 2011 [1].
VTI1A-TCF7L2 fusion transcripts were detected in three out of 97
(3%) CRCs, as well as the colon cancer cell line NCI-H508. In
NCI-H508, the fusion is caused by a ,540 kb deletion between
the genes VTI1A and TCF7L2. TCF7L2 encodes the TCF4
transcription factor, which dimerizes with b-catenin. b-catenin is
involved in regulation of the WNT-signaling pathway, which is
commonly altered in the majority, if not all, CRCs [5]. Depletion
of the VTI1A-TCF7L2 fusion transcript resulted in significant loss
of anchorage independent growth in the fusion positive CRC cell
line NCI-H508 [1].
Frequent mutations in a polyadenine tract within the TCF7L2
gene have previously been reported for CRC, especially in
microsatellite instable tumors [6]. Microsatellite stable tumors
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have, however, also recently been shown to harbor frequent
mutations in the TCF7L2 gene, indicating a possible important
function in CRC biology [7].
In this study, we aimed to investigate further the presence and
variants of VTI1A-TCF7L2 fusions in CRC. We have analyzed
deep sequencing whole-genome and transcriptome data from
CRC for related fusions involving one of the fusion partners, and
for novel fusion breakpoints. The recurrence of the VTI1A-
TCF7L2 fusion, and a new fusion transcript between TCF7L2 and
the novel partner gene RP11-57H14.3, was analyzed in a series of
CRCs and normal samples.
Materials and Methods
Material
A total of 106 CRC tissue samples and 14 paired normal
samples from two independent patient series, Series 1 and Series 2,
were screened for presence of the fusion transcripts. All CRCs are
from patients treated surgically at hospitals in the Oslo region,
Norway. The two patient series included both microsatellite stable
(n = 85) and instable (n = 20) CRCs (one sample not scored), as
assessed by previous studies [8–10]. The series were enriched for
clinical stages II and III CRC (52 stage II, 53 stage III, and 1 stage
IV). Staging was in accordance to the American Joint Cancer
Committee/Union for International Cancer Control (AJCC/
UICC). The 14 paired normal samples from Series 1 were
collected from visually disease free areas of colonic mucosa. The
research biobanks have been registered according to national
legislation, and the study has been approved by the Regional
Committee for Medical Research Ethics (numbers 2781 and 236-
2005-16141).
A total of 21 colorectal cell lines were included [11]. The cell
lines HCT116, HCT15, LoVo, NCI-H508, RKO, SW48, and
SW620 were purchased from the American Type Culture
Collection (ATCC, Manassas, VA, USA). The cell lines Co115,
Colo320, EB, FRI, HT29, IS1, IS2, IS3, LS1034, LS174T,
SW480, TC7, TC71, and V9P were kindly provided by Dr.
Richard Hamelin, Inserm, France. Identities of the cell lines were
verified by the AmpFLSTR Identifiler PCR Amplification Kit
(Applied Biosystems by Life Technologies, Carlsbad, CA, USA).
Additionally, we screened twenty normal tissues from miscella-
neous sites of the body for the TCF7L2 involving fusion transcripts
(adipose, bladder, brain, cervix, colon, esophagus, heart, kidney,
liver, lung, ovary, placenta, prostate, skeletal muscle, spleen,
stomach, testes, thymus, thyroid and trachea; FirstChoice Human
Normal Tissue Total RNA, each a pool of RNA from at least three
individuals, with the exception of an individual sample from the
stomach; Ambion, Applied Biosystems by Life Technologies,
Carlsbad, CA, USA).
Identification of Fusions from Whole-transcriptome and
Whole-genome Sequencing Data
Paired-end RNA-sequencing data from seven colorectal
cancer cell lines (HCT15, HCT116, HT29, LS1034, RKO,
SW48, and SW480) and from 16 normal tissues of miscella-
neous origins were included in the study. These were all
sequenced using the Illumina GAIIx (cell lines) or HiSeq 2000
(normal tissues; both sequencers from Illumina Inc., San Diego,
CA, USA). The colon cancer RNA-seq data included 220
million 76 bp sequence reads (European Nucleotide Archive
study accession ID ERP002049) [12] and the normal samples
included between 73 and 80 million 50 bp sequence reads
per sample (ArrayExpress accession id [E-MTAB-513] and
European Nucleotide Archive study [EMBL:ERP000546]).
Additionally, we obtained paired-end whole-genome sequences
of the cell lines HCT15, HCT116, HT29 and SW480 to an
average coverage of about 306[12] (Data may be made
available upon request to researchers).
A list of potential fusion transcripts was produced by deFuse
version 0.6.0 [13] on the seven previously mentioned RNA-
sequenced cell lines in addition to the CRC cell line NCI-H508
(analysis id 0c7a79cc-bbaf-4c6d-93e1-866f5f5f3d0d) downloaded
from Cancer Genomics Hub (hosted by the University of
California Santa Cruz, CA, USA), data provided by the Cancer
Cell Line Encyclopedia [14] and 16 tissues from the Illumina
Human Body Map v2. For the cell lines with paired whole-
genome sequence (HCT116, HCT15, HT29 and SW480), RNA
fusion transcripts and DNA breakpoints were identified by nFuse
version 0.2.0 [15]. A fusion nomination required three spanning
read pairs and two split reads from the RNA-seq data.
Detection of Fusion Transcripts by Reverse-transcriptase
PCR
For the VTI1A-TCF7L2 fusion, the same RT-PCR primers
and nested primers were used as in the original publication [1].
For the TCF7L2-RP11-57H14.3 fusion, primers and nested
primers were designed to the fusion transcript breakpoint
sequence, as identified by deFuse, by utilizing the Primer3
web software [16]. The optimal primer sequences (Table S1)
were further ordered from BioNordika Norway AS (Oslo,
Norway) and synthesized by Eurogentec (Lie`ge, Belgium). We
performed sensitive nested RT-PCR with 20+30 cycles for both
assays using 50 ng of cDNA from each sample as input into
first round PCR. The products of the first PCR were diluted to
a final concentration of 1/200 in the nested PCR. The
following cycling protocol was used for all PCR reactions: 15
minutes of HotStarTaq DNA polymerase activation at 95uC, a
three-step cycle of denaturation for 30 seconds at 95uC, primer
annealing for one minute and 15 seconds at optimal primer
melting temperatures (Table S1), and extension for one minute
at 72uC. After the last cycle, a final extension step was
performed at 72uC for 6 minutes. The nested-PCR products
were separated by electrophoresis at 200 V for 30 minutes on a
2% agarose gel and visualized using ethidium bromide and UV
light. Triplicate RT-PCR runs were performed for both assays,
using identical parameters, for all samples. No template negative
controls were included from each cDNA synthesis, first-round
PCR and nested-PCR reactions.
Sanger Sequencing of Fusion Transcript Breakpoints
Samples that were positive for the second replicate RT-PCR
assays, and showed a single nucleotide band on the agarose gel,
were sequenced directly from both sides using both forward and
reverse nested primers. Prior to sequencing, the nested PCR
products were purified using Illustra ExoStar 1-step cleanup (GE
Healthcare, Little Chalfront, UK). The cycle sequencing reactions
were performed using the BigDye Terminator v.3.1 cycle
sequencing kit (Applied Biosystems, Foster City, CA, USA)
following supplier’s recommendation. Further, the sequencing
products were cleaned and purified using BigDye Xterminator
(Applied Biosystems), before they were analyzed by capillary
electrophoresis using the ABI 3730 DNA Analyzer (Applied
Biosystems). The sequences were analyzed using the Sequencing
Analysis v.5.3.1 software.
TCF7L2 Fusion Transcripts in Colorectal Cancer
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Assessment of the Identified Genomic Breakpoint
TCF7L2-RP11-57H14.3 by PCR
The genomic breakpoint identified from whole-genome se-
quencing data, connecting TCF7L2 to RP11-57H14.3 in the colon
cancer cell line HCT116, was validated using PCR.
Primers for genomic PCR (Table S1) were designed to the
genomic breakpoint sequence, as identified by nFuse, using the
same approach as described above for the RT-PCR assays.
Twenty-one CRC cell lines, including HCT116, were tested for
the identified genomic breakpoint using 100 ng of DNA as input
for each reaction. The following cycling protocol was used for the
genomic PCR: 15 minutes of HotStarTaq DNA polymerase
activation at 95uC, a three-step cycle (repeated 35 times) of
denaturation for 30 seconds at 95uC, primer annealing for one
minute and 15 seconds at 60uC and extension for one minute at
72uC. After the last cycle, a final extension step was performed at
72uC for 6 minutes. The PCR products were separated by
electrophoresis at 200 V for 30 minutes on a 2% agarose gel, and
visualized using ethidium bromide and UV light.
Results
RP11-57H14.3 is a Novel Fusion Partner in TCF7L2
Containing Fusion Transcripts
To search for the VTI1A-TCF7L2 fusion and novel fusion
partners, we analyzed paired-end RNA-sequencing data from
eight colon cancer cell lines and sixteen normal tissue samples
from miscellaneous anatomical sites. By applying the software
deFuse, we identified between 16 and 1050 potential fusion
transcripts per sample. From whole genome sequencing data of
four colon cancer cell lines, the nFuse software identified between
70 and 126 potential genomic breakpoints. Of all fusions
identified, only NCI-H508 harbored the VTI1A-TCF7L2 fusion
transcript, with a single breakpoint spanning from exon two in
VTI1A to exon six in TCF7L2, as already reported for this cell line
by Bass et al. [1]. However, we identified a genomic breakpoint
(chr10:114,850,371-114,640,318 (GRCh37)) in the CRC cell line
HCT116 that spanned from the intronic region of TCF7L2 to
upstream of RP11-57H14.3 (ENSG00000225292) with a corre-
sponding RNA fusion (Table 1). RP11-57H14.3 is located in the
intergenic region between VTI1A and TCF7L2 approximately
44 kb upstream of TCF7L2. The predicted genomic breakpoints
correlate with increased genomic coverage in the region between
them, suggesting a genomic duplication causing the fusion
(Figure 1). Both the genomic breakpoint and fusion transcript
between TCF7L2 and RP11-57H14.3 were verified by PCR and
RT-PCR. The identified genomic breakpoint was verified in the
HCT116 cell line, but not detected in any of the 20 other cell lines
tested, thereby reducing the likelihood that the genomic break-
point reflects a common DNA copy number polymorphism.
High Prevalence of TCF7L2-involving Fusion Transcripts,
Both Involving VTI1A and the RP11-57H14.3 Genes
Using the same primers as described by Bass et al. [1] (Figure 2),
we detected VTI1A-TCF7L2 fusion transcripts with different exon-
exon combinations in 45 out of 106 CRC samples (42%) (Table 2).
Fusion transcripts were as well detected from 4 of 14 normal
colonic mucosa samples. Out of the 14 paired tumor-normal
samples, eight pairs were positive exclusively in tumor, three pairs
were positive in both tumor and normal, and one pair positive
exclusively in normal (Table 3). Prevalence of fusion transcripts
was similar in microsatellite stable and instable tumors. Ten out of
21 cell lines, including the NCI-H508, harbored fusion transcripts
of different sizes. Finally, five normal tissue samples from different
anatomical sites of the body expressed the fusion transcripts (Table
S2). Because the RT-PCR results revealed inconsistent results
(Figure S1 and Figure S2), we performed all RT-PCRs in
triplicate, with identical parameters, to investigate recurrence of
fusion transcripts (Table S3). Fusion transcripts were only detected
consistently in all three runs in four samples; three tumor samples
and the NCI-H508 cell line (3.1% of all CRC samples and cell
lines). This frequency is similar to the originally identified
frequency of VTI1A-TCF7L2 transcripts (3%) by Bass et al. [1].
We detected TCF7L2-RP11-57H14.3 fusion transcripts with
different exon-exon combinations in 48 out of 106 CRC samples
(45%; Table 2). Out of the 14 paired tumor-normal samples, five
pairs were positive exclusively in tumor, and four pairs were
positive in both tumor and normal (Table 3). 19 out of 21 cell lines,
harbored fusion transcripts of different sizes. Also, 15 out of 20
normal tissue samples were positive for fusion transcripts (Table
S2). As with the VTI1A-TCF7L2 fusion, we performed all RT-
PCRs in triplicate to investigate the recurrence of fusion
transcripts (Table S3). In total there were 20 samples that
repeatedly tested positive for fusion transcripts; six tumor samples,
five samples from normal tissues and nine cell lines (including the
HCT116 cell line). Interestingly, the NCI-H508 cell line was
negative for TCF7L2-RP11-57H14.3 fusion transcripts in all three
replicates.
We found no correlation between CRCs positive for TCF7L2
containing fusion transcripts involving VTI1A and RP11-57H14.3
(p = 0.33; Fisher’s Exact test). Further, the frequencies of fusion
transcripts were not significantly different between microsatellite
instable vs. stable tumors, nor between clinical stages (data not
shown).
All nested-PCR replicates for both assays contained negative no
template controls. These negative control reactions never
produced detectable PCR-products (Figure S1 and S2).
Chimeric Sequences Generally Covered Intact Exonic
Splice Sites from the Partner Genes
From one of the RT-PCR runs, all samples that were positive
for the fusions and had a single PCR product were selected for
Sanger-sequencing of the chimeric RNA-sequences to identify the
exact breakpoints. For VTI1A-TCF7L2 (n = 25), we obtained
sequences from all 25 such isolated fusion transcript RT-PCR
products, where 24 out of 25 had sequences connecting upstream
sequences of the exons 1, 2, 3, 5 or 7 of VTI1A to downstream
sequences of the exons 4 or 6 of TCF7L2, with preservation of the
same exon-exon boundaries as in the already annotated gene
structures (ENST00000393077 in VTI1A and ENST00000369395
in TCF7L2). One sequenced product did not contain clear exon-
exon boundaries, but connected the two transcripts in middle of
exon 7 in VTI1A and 6 in TCF7L2. In total, seven different fusion
breakpoints were identified (Table S3) including the original
breakpoint between exon 2 of VTI1A and exon 6 of TCF7L2 in
NCI-H508 (Figure 3) [1]. This exact breakpoint was not found in
any of the other samples, but most of the intact fusion transcripts
consisted of the same part of TCF7L2 (n = 17) with some having
exon 4 of TCF7L2 spliced to exon 6 (n = 7). The VTI1A upstream
contribution varied more, having five different combinations
connecting to downstream TCF7L2 parts.
For TCF7L2-RP11-57H14.3 (n = 27), we obtained sequences
from all 27 isolated fusion transcript RT-PCR products, where 26
out of 27 had sequences connecting sequences of exon 4 of
TCF7L2 to sequences of exons 1, 2, or 3 of RP11-57H14.3, also
with preservation of the same exon-exon boundaries as in the
already annotated gene structures (exon numbering is the same as
TCF7L2 Fusion Transcripts in Colorectal Cancer
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Figure 1. The TCF7L2-RP11-57H14.3 fusion transcript, identified in the HCT116 cell line, harbors a rearranged genomic locus. Three
chimeric RNA sequence-reads spanned the fusion transcript breakpoint, passing from exon 4 of TCF7L2 (ENST00000369395) to exon 3 of RP11-
57H14.3 (ENST00000428766), on chromosome 10. Dark colors indicate exons not part of the fusion transcript. RNA-seq expression and DNA-seq
coverage levels are based on sequencing data of the HCT116 cell line. The two gene loci are marked in blue and red boxes. The genomic breakpoint
sequence as identified by nFUSE in the CRC cell line HCT116 is given; spanning from the intronic region of TCF7L2 to upstream of RP11-57H14.3. The
coordinates of the breakpoint (chr10:114,850,371-114,640,318 (GRCh37)) are marked on the chromosome position axis. The location of the
breakpoint correlates well with the increased genomic coverage seen from the genome sequencing data.
doi:10.1371/journal.pone.0091264.g001
Table 1. nFuse and defuse: Verification of the original VTI1A-TCF7L2 fusion transcript and identification of a fusion transcript and
genomic breakpoint involving TCF7L2 and RP11-57H14.3.
Cell line GeneA GeneB Software Split{ Spanning{ Score
HCT116 RP11-57H14.3 TCF7L2 deFuse 3 4 0,84a
nFuse NA 27 5,5b
NCI-H508 VTI1A TCF7L2 deFuse 64 27 0,93a
RP11-57H14.3 is located 44 kb upstream of TCF7L2 on chromosome 10.
a)deFuse probability score,
b)nFuse path score. {) Split reads contain the fusion boundary in the read itself, while spanning reads are paired ends that harbor the fusion boundary within the insert
sequence.
doi:10.1371/journal.pone.0091264.t001
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above for TCF7L2 and according to ENST00000428766 for
RP11-57H14.3). One curious case of chimeric sequence, identified
in the CRC cell line FRI, was a fusion transcript spanning three
genes in a non-canonical genomic order, joining TCF7L2 exon 4
with VTI1A exons 5, 6, and 7, and further extending into RP11-
57H14.3 exons 1, 2, and 3. Also in this unique case the same exon-
exon boundaries were used as in the already annotated gene
structures described above. In total, four different fusion
transcripts were identified involving TCF7L2-RP11-57H14.3, all
occurring in several samples each.
Discussion
We have in the present report identified the gene RP11-
57H14.3 as a novel fusion partner for TCF7L2 in CRC. By
sensitive nested RT-PCR, we have revealed that both the
previously reported VTI1A-TCF7L2 fusion transcripts, and the
herein identified TCF7L2-RP11-57H14.3, are highly frequent
among CRCs, although expressed at low levels. We also detected
expression of the fusion transcripts in normal colonic mucosa, as
well as in normal tissues from other anatomical sites. Triplicate
nested-PCRs to investigate the presence of TCF7L2 involving
fusion transcripts showed variable results, with some samples
initially testing positive for a fusion transcript, but negative when
performing a consecutive run, or vice-versa. However, Sanger
sequencing resulted in confirmation of clean exon to exon
breakpoint junctions, reducing the likelihood that PCR artifacts,
such as polymerase template switching [17], as a cause for the
inconsistency. Negative controls were also performed at all RT-
PCR steps, including cDNA synthesis, first-round PCR and
nested-PCR. None of the negative controls resulted in detectable
products, supporting that the high frequency of fusion transcripts
observed is not a result of PCR contamination (Figure S1 and
Figure S2). Although the fusion transcripts were found at high
frequency within the tested biobank materials, the identification of
TCF7L2-containing fusions from whole-transcriptome sequencing
data was only successful from the two cell lines with matching
genomic breakpoints. These two cell lines did as well have
consistently strong expression of the fusion transcripts, as they
produced consistent and clear RT-PCR results in all replicates.
Based on these results, we suggest that the fusion transcripts
produced between TCF7L2 and either VTI1A or RP11-57H14.3
are expressed at low levels in tumor samples, and some normal
samples. The presence of fusion transcripts expressed at low levels
are consistent with three fusion transcripts we recently identified in
CRC, where AKAP13-PDE8A, COMMD10-AP3S1, and CTB-
35F21.1-PSD2 were identified in 17–58% of 106 primary cancer
tissues [12].
All three partner genes are located on the long arm of
chromosome 10, within 721 kbp, and are all read from the same
strand in the order VTI1A, RP11-57H14.3, TCF7L2 (Figure 2).
This suggests RNA polymerase read-through as a potential
Figure 2. Schematic presentation of the genomic location of VTI1A, RP11-57H14.3 and TCF7L2. All three genes are located within 720 kb on
the same strand on the long arm of chromosome 10. The exon numbering refers to exons annotated in transcripts ENST00000393077 in VTI1A,
ENST00000428766 in RP11-57H14.3 and ENST00000369395 in TCF7L2. Also, the nested PCR assays used for detection of both fusion transcripts are
shown. The red and black arrows represent the first round and second round primers used, respectively.
doi:10.1371/journal.pone.0091264.g002
Table 2. The number of positive fusion transcript PCRs for the samples, run in triplicates.
n=
Strong Positivesa:
VTI1A-TCF7L2
Positivesb:
VTI1A-TCF7L2
Strong Positivesa:
TCF7L2-RP11-57H14.3
Positivesb:
TCF7L2-RP11-57H14.3
Series 1-tumor 14 1 (7.1%) 11 (79%) 4 (29%) 9 (64%)
Series 1-normal 14 0 4 (29%) 0 4 (29%)
Series 2 92 2 (2.2%) 34 (37%) 2 (2.2%) 39 (42%)
Cell lines 21 1 (4.8%) 11 (52%) 9 (43%) 19 (90%)
Normals 20 0 5 (25%) 5 (25%) 15 (75%)
a)Strong positives are defined as testing positive in all RT-PCR replicates.
b)Samples noted as positives have tested positive for the fusion transcript(s) in one or more of the three RT-PCR replicates.
doi:10.1371/journal.pone.0091264.t002
TCF7L2 Fusion Transcripts in Colorectal Cancer
PLOS ONE | www.plosone.org 5 March 2014 | Volume 9 | Issue 3 | e91264
mechanism for generating the VTI1A-TCF7L2 transcripts in the
absence of a corresponding genomic breakpoint. Several reports
have shown that genes in close proximity in the human genome
are expressed as conjoined genes, also called tandem chimeras,
transcripts that are combined of at least part of one exon from two
or more distinct genes that lie on the same chromosome [18–20].
It has been suggested that the expression of conjoined genes
increase the complexity of the human genome by translating into
distinct proteins, or that these transcripts play a role in regulation
of canonical transcript levels. One suggested mechanism for their
generation is that the transcription machinery avoids the
termination signal of the upstream gene and continues transcribing
the downstream gene before terminating at the downstream
termination signal [19,21]. The majority of the conjoined genes
are believed to be expressed at low levels, as they are often
supported by only a single expressed sequence tag or mRNA
sequence in genome databases, which is in line with our
observations of weakly expressed TCF7L2-containing fusion
transcripts in CRC.
The generation of VTI1A-TCF7L2 transcripts may well be
explained as a product of polymerase read-through, but this
cannot be the mechanism of operation for the TCF7L2-RP11-
57H14.3 fusion transcripts. In this case, the exons of TCF7L2 and
RP11-57H14.3 are spliced together in a non-canonical genomic
order using consensus splice-sites. This transcriptional mechanism
has previously been described by Nigro et al. as exon scrambling;
a process where exons are joined accurately at consensus splice
sites, but in an order different from that present in the primary
transcript [22]. They discovered this phenomenon when investi-
gating a candidate tumor suppressor gene (DCC), and identified
that the resulting scrambled transcripts are expressed and found at
relatively low levels in both normal and neoplastic cells. Recently,
Table 3. Matched tumor and normal colonic mucosa from series 1.
VTI1A-TCF7L2 TCF7L2-RP11-57H14.3
Pair # Tumor Normal Tumor Normal
1 Y Y N N
2 Y N N N
3 Y N Y Y
4 Y N Y N
5 Y N Y Y
6 Y N Y N
7 N N N N
8 N N Y N
9 Y Y Y Y
10 N Y Y Y
11 Y N N N
12 Y N N N
13 Y N Y N
14 Y Y Y N
For both fusion transcripts the tumor, or both the tumor and normal samples were frequently positive. In one pair the VTI1A-TCF7L2 fusion transcript was positive only
in the normal sample and not the matched tumor.
doi:10.1371/journal.pone.0091264.t003
Figure 3. Confirmation of the original VTI1A-TCF7L2 fusion transcript breakpoint in the cell line NCI-H508. Sanger sequencing
confirmed the original fusion transcript discovered in NCI-H508, showing the breakpoint sequence spanning exon-exon junctions between exon 2 in
VTI1A and exon 6 in TCF7L2. Bass et al. also discovered three other fusion transcripts by nested-PCR. However, as transcript annotation was not
sufficiently described, we are not able to say if these fusions are identical to some of the transcripts we have identified.
doi:10.1371/journal.pone.0091264.g003
TCF7L2 Fusion Transcripts in Colorectal Cancer
PLOS ONE | www.plosone.org 6 March 2014 | Volume 9 | Issue 3 | e91264
based on deep sequencing of RNA, such scrambled transcripts
from hundreds of genes were identified [23]. This group also
suggested that a substantial fraction of the scrambled transcripts
are circular RNAs, which explain the joining of exons in a non-
canonical linear order. They also found that many of the circular
isoforms were present at levels comparable to their canonical
linear counterparts.
Altogether, these added levels of transcriptional and genomic
complexity is in line with the recent report of the ENCODE
project, reporting substantial reduction in the lengths of intergenic
regions, and increasingly overlapping of genes previously assumed
to be distinct genetic loci, altogether prompting a redefinition of
the concept of a gene [24].
The identification of genomic breakpoints in individual cell lines
for TCF7L2 fusions both involving VTI1A and RP11-57H14.3, is
intriguing. The genomic breakpoints identified coincide well with
the frequently observed fusion transcripts discovered in other
samples which do not have such genomic rearrangements. For the
cell lines with identified genomic breakpoints, the fusion
transcripts were detected at strong levels in all RT-PCR replicates,
suggesting that these cells express the fusion transcripts at higher
levels. Furthermore, the cell line with VTI1A-TCF7L2 genomic
fusion (NCI-H508) was negative for the TCF7L2-RP11-57H14.3
fusion transcripts in all replicates, supporting the ,540 kb
genomic deletion of the intergenic region between VTI1A and
TCF7L2 originally identified by Bass et al.
The presence of the fusion transcripts in both normal cells and
CRC samples together with identification of genomic breakpoints
from individual cancer cell lines, joining the same two genes on the
genome level, are in line with the report of the fusion transcript
JAZF1-JJAZ1 identified in both normal endometrial stromal cells
and endometrial stromal tumors [25]. JAZF1-JJAZ1 is detectable
at the transcript level in normal endometrial stromal cells but
genomic rearrangements are found only in the neoplastic cells. Li
et al. hypothesize that trans-splicing generating these fusion
transcripts, as well as other fusion transcripts, may occur regularly
in normal cells and tissues. Further, they suggest that there may be
a link between trans-splicing generating these fusion transcripts
and the generation of the genomic rearrangements [26]. The
genomic rearrangements or other mechanisms may lead to
overexpression of these fusion transcripts, which may have
oncogenic potential.
The importance of the gene TCF7L2 in CRC development is
favored by its function. TCF7L2 encodes the TCF4 transcription
factor, which is a key down-stream transcription factor in the
WNT/b-catenin-signaling pathway, altered in the majority of
CRCs [5]. The original report of VTI1A-TCF7L2 found that
depletion of the fusion transcript resulted in significant loss of
anchorage independent growth in the fusion positive CRC cell line
NCI-H508 [1]. Frequent mutations in a polyadenine tract within
the TCF7L2 gene have previously been reported for CRC,
especially in microsatellite instable tumors [6]. Furthermore,
microsatellite stable tumors have recently been shown to harbor
frequent mutations in TCF7L2 [7]. The observation that TCF7L2
involving fusion transcripts are detectable in such a large fraction
of CRC samples, but also normal colonic mucosa and other
normal tissue types, reveals that the TCF7L2 fusion transcripts are
neither specific to cancer nor to the colon and rectum. Hence, they
do not have the potential as cancer detection biomarkers as
originally expected. When that is said, the similar fusion transcripts
induced by genomic rearrangements observed in individual cancer
cell lines may yet have oncogenic potential as suggested in the
original study by Bass et al. The phenomenon of genomic
rearrangements observed in cancer cells that correlate with
transcription induced chimeras observed in most normal cells is
in itself intriguing and needs to be explored further.
In conclusion, we have identified the gene RP11-57H14.3 as a
novel fusion partner of TCF7L2. Both this fusion transcript and the
previously reported VTI1A-TCF7L2 are processed into several
different splice variants, and TCF7L2 involving fusion transcripts
are expressed at detectable levels, in a high proportion of CRCs,
and also in normal tissues from both colonic mucosa and from
other anatomical sites. We suggest that these fusion transcripts are
transcription induced chimeras, but that individual cancer cells
have genomic rearrangements that lead to expression of highly
similar fusion transcripts that potentially have a role in cancer
development or progression.
Supporting Information
Figure S1 VTI1A-TCF7L2: Nested-PCR products in tu-
mor samples, matched normals and CRC cell lines run
in triplicate and analyzed on 2% agarose gels. The results
show a much higher degree of fusion-transcript positives than what
has previously been reported for VTI1A-TCF7L2. However, the
results diverge somewhat from run to run. A) Nested-PCR results
from patient series 1 and 2. B) Nested-PCR results from the 21
CRC cell lines and some negative controls. The nested-PCR
product of NCI-H508 seems more abundant compared to the
other products based on the band luminescence. C) Additional
negative controls, including no template controls from cDNA
synthesis, first-round and second-round PCR.
(TIF)
Figure S2 TCF7L2-RP11-57H14.3: Nested-PCR products
in tumor samples, matched normals and CRC cell lines
run in triplicate and analyzed on 2% agarose gels. The
results diverge somewhat for each replicate. A) Nested-PCR results
from patient series 1 and 2. B) Nested-PCR results from the 21
CRC cell lines and some negative controls. There are at least three
PCR-products from the cell line HCT116, which are present and
identical in all replicates. C) Additional negative controls,
including no template controls from cDNA synthesis, first-round
and second-round PCR.
(TIF)
Table S1 Primers used in this study.
(DOCX)
Table S2 Both fusion transcripts involving TCF7L2 were
detected, by RT-PCR, in several human tissues.
(DOCX)
Table S3 Total overview of nested RT-PCR and Sanger
sequencing confirmation of fusion transcripts.
(DOCX)
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